There are rapid antigen tests, less accurate but take only 15 mins. But RAPs would be faster and can scale more easily. What applications for it we'd see will be dependent on what kind of accuracy they're able to achieve, but hopefully they can get some promising results.
If it has good accuracy then on the scalability front it would be unmatched. Like imagine if the gov embeds it in an app of their's, so any time there's an outbreak they encourage everyone (or only those symptomatic, depending on whether it works only with symptomatic or also asymptomatic cases) go on and take the test, like overnight they'd hopefully have a pretty good rough picture of where the virus might be and what portion of the population might be infected.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp expands COVID-19 clinical program
Ann: ResApp expands COVID-19 clinical program, page-21
-
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online